Brian Eades, MD
Cardiovascular Disease · McKinney, TXNPI 1538151170
Payments from drug & device makers
Across 436 payments — averaging $157.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$45K
- CSL Behring$14K
- Abbott$3K
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$899
- Merck$863
- Cardiovascular Systems Inc.$755
- plus $4K from 34 others
What the payments were for
- Speaking & faculty fees$41,83676%
- Travel & lodging$6231%
- Food & beverage$12,21022%
- Education$790%
- Entertainment$1520%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 138 | $45,098 |
| CSL Behring | 7 | $13,701 |
| Abbott | 64 | $3,287 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 28 | $899 |
| Merck | 44 | $863 |
| Cardiovascular Systems Inc. | 6 | $755 |
| Novo Nordisk | 24 | $519 |
| Itamar Medical Inc | 4 | $497 |
| AstraZeneca | 10 | $262 |
| Heartflow, Inc. | 5 | $241 |
| Regeneron Healthcare Solutions, Inc. | 9 | $223 |
| Amarin Pharma, Inc. | 7 | $197 |
| Johnson & Johnson | 10 | $179 |
| Medtronic | 3 | $179 |
| Esperion Therapeutics, Inc. | 11 | $174 |
| Boehringer Ingelheim | 8 | $152 |
| Cleerly, Inc. | 2 | $149 |
| Vifor Pharma, Inc. | 8 | $137 |
| Bayer | 7 | $119 |
| Novartis | 5 | $118 |
| Recor Medical Inc | 1 | $117 |
| Pfizer | 4 | $77 |
| Scpharmaceuticals Inc. | 4 | $70 |
| Impulse Dynamics (USA) Inc. | 2 | $69 |
| E.r. Squibb & Sons, L.L.C. | 3 | $64 |
| Sanofi-aventis U.S. LLC | 3 | $63 |
| Cvrx, Inc. | 3 | $56 |
| Lexicon Pharmaceuticals, Inc. | 2 | $44 |
| Astellas Pharma US Inc | 3 | $44 |
| Kestra Medical Technology Services, Inc. | 1 | $37 |
| Aurinia Pharma U.S., Inc. | 1 | $34 |
| Shockwave Medical, Inc | 1 | $33 |
| Edwards Lifesciences | 1 | $28 |
| Biotronik Inc. | 1 | $22 |
| Regeneron | 1 | $21 |
| Chiesi USA, Inc. | 1 | $16 |
| Irhythm Technologies, Inc. | 1 | $15 |
| Inspire Medical Systems, Inc. | 1 | $14 |
| Baxter Healthcare | 1 | $13 |
| Digirad Health, Inc | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Repatha$43,033
- Peripheral Orbital Atherectomy System$605
- JOT DX$556
- WatchPat$281
- Ozempic$243
- WatchPATONE$216
- GALLANT$152
- FFRct$147
- COREVALVE EVOLUT R$143
- Confirm Rx$133
- VERQUVO$125
- FARXIGA$121
- Paradise Ultrasound Renal Denervation System$117
- Vascepa$117
- AVEIR$112
How this compares
$68,599 in reported general payments places this provider in the 85th percentile of 1,515 cardiovascular disease providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 144 | $167,500 |
| Repatha SureclickEvolocumab | 193 | $152,177 |
| EntrestoSacubitril/Valsartan | 67 | $86,393 |
| XareltoRivaroxaban | 48 | $61,833 |
| FarxigaDapagliflozin Propanediol | 22 | $33,368 |
| VerquvoVericiguat | 20 | $32,972 |
| Praluent PenAlirocumab | 15 | $13,182 |
| Ezetimibe | 317 | $6,571 |
| Metoprolol Succinate | 329 | $3,966 |
| Rosuvastatin Calcium | 243 | $3,824 |
| Losartan Potassium | 200 | $2,405 |
| Fenofibrate | 58 | $1,529 |
| Ranolazine ErRanolazine | 18 | $1,517 |
| Carvedilol | 173 | $1,399 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 21 | $1,331 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $77 | $167,500144 claims |
| NovartisEntresto | $118 | $86,39367 claims |
| Johnson & JohnsonXarelto | $179 | $61,83348 claims |
| AstraZenecaFarxiga | $262 | $33,36822 claims |
| MerckVerquvo | $863 | $32,97220 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,515 cardiovascular disease providers in Texas.
Other cardiovascular disease in McKinney
- Faisal WahidMcKinney$3.4M
- Wael Abo-AudaMcKinney$960K
- Muhammad KhanMcKinney$567K
- Ramin Farzaneh-FarDallas$17.1M
- Jeffrey GladdenDallas$15.8M
- Ann NavarDallas$14.5M
- David BrabhamAmarillo$11.5M
- Justin GrodinDallas$6.2M
- Christie BallantyneHouston$4.6M
- Syed NaqviHouston$3.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.